Premium
Outcome of Transfusion of K:11 Erythrocytes in a Patient with Anti‐K11 Antibody
Author(s) -
Kelley Carolyn M.,
Karwal Mark W.,
Schlueter Annette J.,
Olson John D.
Publication year - 1998
Publication title -
vox sanguinis
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.68
H-Index - 83
eISSN - 1423-0410
pISSN - 0042-9007
DOI - 10.1046/j.1423-0410.1998.7430205.x
Subject(s) - antibody , red cell , medicine , adverse effect , red blood cell , blood transfusion , clinical significance , cell , immunology , biology , biochemistry
Background and objectives: The clinical significance of anti‐K11 in red cell transfusion therapy is unknown. We report the outcome of transfusion of K:11 erythrocytes into a patient with a known anti‐K11 antibody. Materials and methods: The patient was monitored clinically following transfusion of 11 units of K: 11 erythrocytes. A red cell survival study with K: 11 erythrocytes and a monocyte monolayer assay (MMA) were performed. Results: No adverse clinical outcome was detected. The red cell survival study showed normal survival of K: 11 erythrocytes, and the MMA showed no increase in reactive monocytes. Conclusion: These findings suggest that K:11 red cells can safely be transfused to individuals with anti‐K11 antibody.